

Adherium Secures R&D Loan Facility

Melbourne, Australia – 4 December 2024 - [Adherium Limited](#) (ASX:ADR), a global leader in digital inhaler technology is pleased to advise it has entered into a \$674,000 R&D loan facility with Endpoints Capital Pty Ltd.

The R&D loan facility has been established against the Company's anticipated R&D tax rebate for the FY24 period and is subject to a pro-rata annual interest rate of 16%. Funds from the loan facility have been received.

Under the loan facility, Adherium can access up to 80% of its accrued RDTI rebate. Eligible RDTI expenditure must be verified by an accounting firm approved by Endpoints Capital. Repayment is timed to coincide with receipt of Adherium's FY24 RDTI refund, expected by March 2025.

Early access to these funds provides additional working capital as the Company scales its patient onboarding and ramps up sales and delivery across a range of customers in the key United States remote patient monitoring market.

Adherium CFO, Daniel Kaplon commented, "A specialist loan facility of this nature, secured against the R&D rebate is an attractive form of non-dilutive funding for Adherium. We are pleased to have worked with Endpoints Capital on this straightforward and effective debt facility."

Learn more at [adherium.com](#)

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Daniel Kaplon
Adherium Limited
Chief Financial Officer
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK
Director
haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of



ASX Release

health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at [adherium.com](https://www.adherium.com)